A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral lung cancer therapies, such as Pfizer’s Xalkori and Novartis’ Zykadia.

AstraZeneca has previously said it believes Tagrisso could generate peak sales of $3 billion a year, making it a key product in the group’s growing oncology portfolio.

Its prospects received a boost on Monday when a rival drug from Clovis Oncology hit a snag, with U.S. health regulators asking for more data and Clovis reporting lower-than-expected confirmed response rates.


(Reporting by Ben Hirschler; editing by Jason Neely)

Source: Reuters Health